Type 2 inflammation plays an important role in CRSwNP—a chronic disease with a high symptom burden and substantial unmet need

Patients with inadequately controlled CRSwNP can experience the following1-5:

  • Nasal obstruction
  • Nasal congestion
  • Difficulty breathing through the nose
  • Loss of smell
  • Social, emotional, and physical consequences
  • Increased need for sino-nasal surgery
  • Increased OCS use

Patients with CRSwNP often have comorbid diseases driven by Type 2 inflammation, which involves cytokines IL-4, IL-13, and IL-55-7

  • ~50% asthma
  • 14% NSAID-ERD

CRSwNP can remain uncontrolled in patients on standard-of-care therapies, which can lead to multiple sino-nasal surgeries and cycles of OCS use4,5

  • NSAID-ERD, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; OCS, oral corticosteroid.
  1. Palmer J, Messina J, Biletch R, Grosel K, Mahmoud R. Health care for chronic rhinosinusitis (CRS) symptoms—a cross-sectional, population-based survey of US adults meeting symptom criteria for CRS. Poster presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; March 3-6, 2017; Atlanta, GA.
  2. Data on file, Sanofi US. CSR SAR231893/REGN668, 2018.
  3. Liu T, Cooper T, Earnshaw J, Cervin A. Disease burden and productivity cost of chronic rhinosinusitis patients referred to a tertiary centre in Australia. Aust J Otolaryngol. 2018;1:5. doi:10.21037/ajo.2018.01.03
  4. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555.
  5. Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070.
  6. Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373-377.
  7. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
  8. DUPIXENT Prescribing Information.
  9. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.

Mechanism of Action

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling

DUPIXENT is a human monoclonal antibody that specifically binds to the IL-4Rα subunit shared by receptor complexes for IL-4 and IL-138

  • DUPIXENT inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor

DUPIXENT inhibits IL-4 and IL-13 cytokine-induced inflammatory responses that contribute to8,9:

  • Eosinophil activation and trafficking
  • IgE release
  • Mast cell activation
  • Mucus hypersecretion


See how eligible patients can access
support for DUPIXENT



in patients with uncontrolled CRSwNP